https://scholars.lib.ntu.edu.tw/handle/123456789/517561
標題: | Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia | 作者: | TSEN-FANG TSAI Choi G.S. Kim B.J. Kim M.-B. Ng C.F. Kochhar P. Jasper S. Brotherton B. Orban B. Lulic Z. |
公開日期: | 2018 | 出版社: | Blackwell Publishing Ltd | 卷: | 45 | 期: | 7 | 起(迄)頁: | 799-804 | 來源出版物: | Journal of Dermatology | 摘要: | Treatment with 5α-reductase inhibitors has been associated with sexual adverse events such as impotence (erectile dysfunction) and decreased libido. The primary objective of this study was to evaluate adverse events related to sexual function, based on their frequency, duration, persistence and associated treatment discontinuations, in men treated with dutasteride for androgenetic alopecia. Participants were randomized to receive double-blind dutasteride 0.5 mg or placebo once daily for 24 weeks, followed by open-label dutasteride 0.5 mg for an additional 24 weeks. Sexual adverse events were followed up until resolution or for up to 24 weeks after the last dose. Overall, 117 men, 23–50 years of age, were randomized. The incidence of sexual adverse events was approximately twofold higher in the dutasteride group (16%) than the placebo group (8%) during the double-blind period; the overall incidence of sexual adverse events was lower (5%) during the open-label period. All adverse events were mild to moderate in severity and considered treatment-related. The adverse events resolved while on study treatment or after the end of treatment and did not lead to treatment discontinuation. A limitation of this study was the small sample size. The sexual adverse events of impotence, decreased libido and ejaculation disorders reported in this study were expected and reversible. ? 2018 GlaxoSmithKline. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045713586&doi=10.1111%2f1346-8138.14329&partnerID=40&md5=97dbcaf4f6c9f544e929389f85a1a37c https://scholars.lib.ntu.edu.tw/handle/123456789/517561 |
ISSN: | 0385-2407 | DOI: | 10.1111/1346-8138.14329 | SDG/關鍵字: | dutasteride; placebo; dutasteride; placebo; steroid 5alpha reductase inhibitor; adult; Article; controlled study; disease duration; disease severity; double blind procedure; drug safety; ejaculation disorder; erectile dysfunction; follow up; hair growth; human; hypokalemia; impotence; incidence; International Index of Erectile Function; intervertebral disk hernia; libido disorder; major clinical study; male; male sexual dysfunction; male type alopecia; multicenter study; open study; parallel design; patient satisfaction; prospective study; randomized controlled trial; rhinopharyngitis; sexual satisfaction; age; alopecia; chemically induced; drug effect; libido; middle aged; psychosexual disorder; treatment outcome; young adult; 5-alpha Reductase Inhibitors; Adult; Age Factors; Alopecia; Double-Blind Method; Dutasteride; Humans; Incidence; Libido; Male; Middle Aged; Placebos; Prospective Studies; Sexual Dysfunctions, Psychological; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。